Better conduct of clinical trials: The control group in critical care trials
- 1 January 2009
- journal article
- better conduct-of-clinical-trials
- Published by Ovid Technologies (Wolters Kluwer Health) in Critical Care Medicine
- Vol. 37 (Supplement), S80-S90
- https://doi.org/10.1097/ccm.0b013e3181922bf4
Abstract
Objective: To review trial design issues related to control groups. Design: Review of the literature with specific reference to critical care trials. Main Results and Conclusions: Performing randomized controlled trials in the critical care setting presents specific problems: studies include patients with rapidly lethal conditions, the majority of intensive care patients suffer from syndromes rather than from well-definable diseases, the severity of such syndromes cannot be precisely assessed, and the treatment consists of interacting therapies. Interactions between physiology, pathophysiology, and therapies are at best marginally understood and may have a major impact on study design and interpretation of results. Selection of the right control group is crucial for the interpretation and clinical implementation of results. Studies comparing new interventions with current ones or different levels of current treatments have the problem of the necessity of defining “usual care.” Usual care controls without any constraints typically include substantial heterogeneity. Constraints in the usual therapy may help to reduce some variation. Inclusion of unrestricted usual care groups may help to enhance safety. Practice misalignment is a novel problem in which patients receive a treatment that is the direct opposite of usual care, and occurs when fixed-dose interventions are used in situations where care is normally titrated. Practice misalignment should be considered in the design and interpretation of studies on titrated therapies.Keywords
This publication has 51 references indexed in Scilit:
- Critical care services and trial methodology: Even at the turning of the tide*Critical Care Medicine, 2007
- Multiple-center, randomized, placebo-controlled, double-blind study of the nitric oxide synthase inhibitor 546C88: Effect on survival in patients with septic shock*Critical Care Medicine, 2004
- The Role of a Journal in a Scientific ControversyAmerican Journal of Respiratory and Critical Care Medicine, 2003
- Increased Mortality Associated with Growth Hormone Treatment in Critically Ill AdultsNew England Journal of Medicine, 1999
- Elevation of Systemic Oxygen Delivery in the Treatment of Critically Ill PatientsNew England Journal of Medicine, 1994
- Double-blind, Placebo-controlled Trial of Antithrombin III Concentrates in Septic Shock With Disseminated Intravascular CoagulationChest, 1993
- Evidence-Based MedicineJAMA, 1992
- Treatment of Gram-Negative Bacteremia and Septic Shock with HA-1A Human Monoclonal Antibody against EndotoxinNew England Journal of Medicine, 1991
- The Randomized Clinical TrialNew England Journal of Medicine, 1972
- The Clinical TrialNew England Journal of Medicine, 1952